UA62926C2 - Methods for treatment or prevention of interstitial cystitis and dosage form containing duloxetine - Google Patents

Methods for treatment or prevention of interstitial cystitis and dosage form containing duloxetine Download PDF

Info

Publication number
UA62926C2
UA62926C2 UA98094777A UA98094777A UA62926C2 UA 62926 C2 UA62926 C2 UA 62926C2 UA 98094777 A UA98094777 A UA 98094777A UA 98094777 A UA98094777 A UA 98094777A UA 62926 C2 UA62926 C2 UA 62926C2
Authority
UA
Ukraine
Prior art keywords
duloxetine
treatment
interstitial cystitis
active ingredient
prevention
Prior art date
Application number
UA98094777A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of UA62926C2 publication Critical patent/UA62926C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Threshing Machine Elements (AREA)
  • Processing Of Meat And Fish (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nozzles (AREA)
  • Heat Treatment Of Articles (AREA)
  • Transplanting Machines (AREA)
  • Pistons, Piston Rings, And Cylinders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Steroid Compounds (AREA)
UA98094777A 1996-03-11 1997-07-03 Methods for treatment or prevention of interstitial cystitis and dosage form containing duloxetine UA62926C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1315796P 1996-03-11 1996-03-11
PCT/US1997/003410 WO1997033880A1 (en) 1996-03-11 1997-03-07 Methods of treating or preventing interstitial cystitis

Publications (1)

Publication Number Publication Date
UA62926C2 true UA62926C2 (en) 2004-01-15

Family

ID=21758595

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98094777A UA62926C2 (en) 1996-03-11 1997-07-03 Methods for treatment or prevention of interstitial cystitis and dosage form containing duloxetine

Country Status (23)

Country Link
EP (1) EP0888330B1 (de)
JP (1) JP2000506863A (de)
KR (1) KR19990087671A (de)
CN (1) CN1217721A (de)
AT (1) ATE239467T1 (de)
AU (1) AU730448B2 (de)
BR (1) BR9708027A (de)
CA (1) CA2250288A1 (de)
CZ (1) CZ287798A3 (de)
DE (1) DE69721747T2 (de)
DK (1) DK0888330T3 (de)
EA (1) EA001325B1 (de)
ES (1) ES2197993T3 (de)
HU (1) HUP9902884A3 (de)
IL (1) IL126159A (de)
NO (1) NO984160L (de)
NZ (1) NZ331811A (de)
PL (1) PL328959A1 (de)
PT (1) PT888330E (de)
RO (1) RO117296B1 (de)
UA (1) UA62926C2 (de)
WO (1) WO1997033880A1 (de)
YU (1) YU39598A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344057C (en) 1998-09-15 2008-11-18 Eli Lilly And Company Treatment of persistent pain
EP1383495A1 (de) * 2001-03-29 2004-01-28 Eli Lilly And Company Duloxetine zur verminderung von hitzewallungen
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
DE10247689A1 (de) * 2002-10-12 2004-04-22 Martin Rahe Implantat in der Harnblase
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
EP1904039A2 (de) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Kontrollierte duloxetin-dosierungsfreisetzungsformel
EP2099492B1 (de) * 2006-12-27 2013-06-05 LEK Pharmaceuticals d.d. Duloxetin-zusammensetzung
EP1938840A1 (de) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetinzusammensetzung
EP2018860A1 (de) * 2007-07-16 2009-01-28 LEK Pharmaceuticals D.D. Duloxetinzusammensetzung
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
RU2719929C1 (ru) * 2018-12-17 2020-04-23 Юрий Анатольевич Игнашов Способ выбора лечения женщин с синдромом болезненного мочевого пузыря

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574474A (en) * 1897-01-05 Course-indicating apparatus
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence

Also Published As

Publication number Publication date
NO984160D0 (no) 1998-09-10
CA2250288A1 (en) 1997-09-18
DE69721747T2 (de) 2004-04-01
EP0888330A1 (de) 1999-01-07
IL126159A (en) 2003-01-12
EP0888330A4 (de) 1999-04-07
CN1217721A (zh) 1999-05-26
HUP9902884A2 (en) 2000-07-28
EA199800816A1 (ru) 1999-02-25
RO117296B1 (ro) 2002-01-30
AU730448B2 (en) 2001-03-08
ATE239467T1 (de) 2003-05-15
AU2196297A (en) 1997-10-01
NZ331811A (en) 2001-04-27
DE69721747D1 (de) 2003-06-12
EA001325B1 (ru) 2001-02-26
PT888330E (pt) 2003-09-30
PL328959A1 (en) 1999-03-01
CZ287798A3 (cs) 1999-05-12
IL126159A0 (en) 1999-05-09
JP2000506863A (ja) 2000-06-06
NO984160L (no) 1998-09-10
DK0888330T3 (da) 2003-09-01
WO1997033880A1 (en) 1997-09-18
EP0888330B1 (de) 2003-05-07
KR19990087671A (ko) 1999-12-27
HUP9902884A3 (en) 2000-12-28
YU39598A (sh) 1999-09-27
ES2197993T3 (es) 2004-01-16
BR9708027A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
Staskin et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study
US20090012161A9 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
JP5661900B2 (ja) アルコール摂取症状を軽減するための方法
EP3318249A1 (de) Dimethylfumarat-dosierungsschemata für die behandlung der multiplen sklerose
RU2000107124A (ru) Лечение опосредуемых клеткой иммунных болезней
JPH11506433A (ja) 結腸送達のための多重腸溶性ポリマーコーティングを有するビサコジル投与形態
WO2012162669A1 (en) Methods of treating multiple sclerosis and preserving and/or increasing myelin content
GB2487808A (en) Oral adjuvant or formulation comprising a lipid and an alcohol
UA62926C2 (en) Methods for treatment or prevention of interstitial cystitis and dosage form containing duloxetine
WO2003103659A1 (ja) 過活動膀胱治療剤
KR20190080875A (ko) 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
JP2950845B2 (ja) アゼラスチンを含有する調節された作用物質放出性の経口適用医薬調製剤及びその製法
CN102526006B (zh) 单羧酸和二羧酸的酰胺化物在肾病治疗中的应用
CA2442410A1 (en) Duloxetine for treatment of hot flashes
CN101889996A (zh) 含有坦索罗辛的直肠给药组合物
US6150396A (en) Methods of treating or preventing interstitial cystitis
KR20240065134A (ko) 피부 방사선 손상의 예방 및 치료를 위한 조성물 및 방법
US20050154041A1 (en) Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
WO2022221988A1 (en) Pharmaceutical hydronidone formulations for diseases
JP5575927B2 (ja) ペントキシフィリンの便秘の予防または治療における応用
US12083133B2 (en) Use of cholecalciferol as adjuvant in the treatment of muscular dystrophies
CN108853017A (zh) 一种雌三醇纳米口服制剂的组方与制备工艺
AU4389201A (en) Methods of treating or preventing interstitial cystitis
CN111035626B (zh) 一种载罗氟司特药物的plga生物降解缓释制剂的制备方法
ES2309148T3 (es) Composiciones farmaceuticas que comprenden pravastatina para reducir los niveles de colesterol ldl.